|
業務類別
|
Biotechnology |
|
業務概覽
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology. |
| 公司地址
| 11 Hurley Street, Cambridge, MA, USA, 02141 |
| 電話號碼
| +1 617 401-9000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.editasmedicine.com |
| 員工數量
| 87 |
| Dr. Gilmore O’Neill, M.B. |
Director, Chief Executive Officer and President |
美元 686.57K |
28/04/2026 |
| Dr. Linda C. Burkly, PhD |
Executive Vice President and Chief Scientific Officer |
美元 517.17K |
28/04/2026 |
| Ms. Amy Parison |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 394.20K |
28/04/2026 |
|
|
| Mr. Andrew J. Hirsch |
Independent Director |
28/04/2026 |
| Dr. Jessica Hopfield, PhD |
Chairman of the board |
28/04/2026 |
| Dr. David T. Scadden, M.D. |
Independent Director |
28/04/2026 |
| Ms. Bernadette M. Connaughton |
Independent Director |
28/04/2026 |
| Dr. Gilmore O’Neill, M.B. |
Director, Chief Executive Officer and President |
28/04/2026 |
| Dr. Elliott M. Levy, M.D. |
Independent Director |
28/04/2026 |
|
|
|
|
